OBJECTIVE: To determine whether variants in the estrogen receptors 1 (alpha) and 2 (beta) (ESR1 and ESR2) genes are associated with cognitive impairment in non-demented elderly men and women. BACKGROUND: Several single nucleotide polymorphisms (SNPs) on ESR1 and ESR2 genes have been associated with a range of hormone sensitive diseases such as breast cancer and osteoporosis. Genetic variations in ESR may also influence cognitive aging but are less studied, especially among men. METHODS: We studied 2527 participants enrolled in an ongoing prospective study of community-dwelling elders. Four SNPs from ESR1 and four from ESR2 were analyzed. We measured cognitive function with the Modified Mini-Mental Status Examination (3MS) at baseline and biannually; cognitive impairment was defined as a decline of five or more points over 4 years. We calculated odds of developing cognitive impairment across SNPs using gender-stratified logistic regression and adjusted analyses for age, education, baseline 3MS score and in addition for race. RESULTS: One thousand three hundred and forty-three women (mean age 73.4) and 1184 men (mean age 73.7) comprised our cohort. Among women, after multivariate adjustment, two of the ESR1 SNPs (rs8179176, rs9340799) and two of the ESR2 SNPs (rs1256065, rs1256030) were associated with likelihood of developing cognitive impairment, although the association for rs8179176 was of trend level significance. In men, one of the ESR1 SNPs (rs728524) and two of the ESR2 (rs1255998, rs1256030) were associated with cognitive impairment. Further adjustment for race attenuated the results somewhat. There was no association between any ESR SNP and level of bioavailable estradiol but testosterone level did vary among two of the SNPs (p<0.05). CONCLUSION: We found that among non-demented community elders, several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment. These findings suggest that estrogen receptor genetic variants may play a role in cognitive aging.
OBJECTIVE: To determine whether variants in the estrogen receptors 1 (alpha) and 2 (beta) (ESR1 and ESR2) genes are associated with cognitive impairment in non-demented elderly men and women. BACKGROUND: Several single nucleotide polymorphisms (SNPs) on ESR1 and ESR2 genes have been associated with a range of hormone sensitive diseases such as breast cancer and osteoporosis. Genetic variations in ESR may also influence cognitive aging but are less studied, especially among men. METHODS: We studied 2527 participants enrolled in an ongoing prospective study of community-dwelling elders. Four SNPs from ESR1 and four from ESR2 were analyzed. We measured cognitive function with the Modified Mini-Mental Status Examination (3MS) at baseline and biannually; cognitive impairment was defined as a decline of five or more points over 4 years. We calculated odds of developing cognitive impairment across SNPs using gender-stratified logistic regression and adjusted analyses for age, education, baseline 3MS score and in addition for race. RESULTS: One thousand three hundred and forty-three women (mean age 73.4) and 1184 men (mean age 73.7) comprised our cohort. Among women, after multivariate adjustment, two of the ESR1 SNPs (rs8179176, rs9340799) and two of the ESR2 SNPs (rs1256065, rs1256030) were associated with likelihood of developing cognitive impairment, although the association for rs8179176 was of trend level significance. In men, one of the ESR1 SNPs (rs728524) and two of the ESR2 (rs1255998, rs1256030) were associated with cognitive impairment. Further adjustment for race attenuated the results somewhat. There was no association between any ESR SNP and level of bioavailable estradiol but testosterone level did vary among two of the SNPs (p<0.05). CONCLUSION: We found that among non-demented community elders, several SNPs in the ESR1 and ESR2 genes were associated with risk of developing cognitive impairment. These findings suggest that estrogen receptor genetic variants may play a role in cognitive aging.
Authors: H Maruyama; H Toji; C R Harrington; K Sasaki; Y Izumi; T Ohnuma; H Arai; M Yasuda; C Tanaka; P C Emson; S Nakamura; H Kawakami Journal: Arch Neurol Date: 2000-02
Authors: J C Lambert; J M Harris; D Mann; H Lemmon; J Coates; A Cumming; D St-Clair; C Lendon Journal: Neurosci Lett Date: 2001-06-29 Impact factor: 3.046
Authors: L Westberg; F Baghaei; R Rosmond; M Hellstrand; M Landén; M Jansson; G Holm; P Björntorp; E Eriksson Journal: J Clin Endocrinol Metab Date: 2001-06 Impact factor: 5.958
Authors: K M Mattila; K Axelman; J O Rinne; M Blomberg; T Lehtimäki; P Laippala; M Röyttä; M Viitanen; L Wahlund; B Winblad; L Lannfelt Journal: Neurosci Lett Date: 2000-03-17 Impact factor: 3.046
Authors: M L Brandi; L Becherini; L Gennari; M Racchi; A Bianchetti; B Nacmias; S Sorbi; P Mecocci; U Senin; S Govoni Journal: Biochem Biophys Res Commun Date: 1999-11-19 Impact factor: 3.575
Authors: Brian Leyland-Jones; Kathryn P Gray; Mark Abramovitz; Mark Bouzyk; Brandon Young; Bradley Long; Roswitha Kammler; Patrizia Dell'Orto; Maria Olivia Biasi; Beat Thürlimann; Vernon Harvey; Patrick Neven; Laurent Arnould; Rudolf Maibach; Karen N Price; Alan S Coates; Aron Goldhirsch; Richard D Gelber; Olivia Pagani; Giuseppe Viale; James M Rae; Meredith M Regan Journal: Breast Cancer Res Treat Date: 2015-11-21 Impact factor: 4.872